dimethyl 3-bromocyclopentene-1,2-dicarboxylate | 122130-99-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: dimethyl 3-bromocyclopentene-1,2-dicarboxylate
• 英文别名: 3-bromo-cyclopent-1-ene-1,2-dicarboxylic acid dimethyl ester；3-bromo-1-cyclopentene-1,2-dicarboxylic acid dimethylester
• CAS: 122130-99-8
• 化学式: C₉H₁₁BrO₄
• 分子量: 263.088
• InChiKey: ANKPIQRQTLQXLO-UHFFFAOYSA-N

物化性质

• 沸点：
  289.3±40.0 °C(Predicted)
• 密度：
  1.569±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  dimethyl 3-bromocyclopentene-1,2-dicarboxylate 在 氢氧化钾 、 sodium formate 作用下， 生成 dimethyl 3-(1-ethoxy-2-bromoethoxy)cyclopentene-1,2-dicarboxylate
  参考文献：
  名称：

  自由基环化到2（5 ）-呋喃酮和马来酸酯电泳上，导致螺旋和线性稠合的γ-内酯环系统

  摘要：

  涉及α-缩醛甲基中心和2（5 ）-呋喃酮和马来酸酯电泳的自由基环化反应可轻松合成螺旋和线性稠合的γ-内酯环系统，例如（6），（10），（14）和（19），在银杏内酯中发现。

  DOI：

  10.1016/s0040-4039(00)82137-1
• 作为产物：
  描述：

  1-环戊烯-1,2-二甲酸二甲酯 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 氯仿 为溶剂， 反应 0.25h， 以74%的产率得到dimethyl 3-bromocyclopentene-1,2-dicarboxylate
  参考文献：
  名称：

  自由基环化到2（5 ）-呋喃酮和马来酸酯电泳上。银杏内酯中螺旋和线性稠合的γ-内酯环系统的方法

  摘要：

  涉及α-缩醛甲基中心，2（5 ）-呋喃酮和马来酸酯电泳的分子内自由基环化反应可轻松合成螺旋和线性稠合的γ-内酯环系统（5），（6），（7）和（ 8）存在于由银杏树产生的“银杏内酯”即（1）和（2）中。

  DOI：

  10.1016/s0040-4020(01)81099-1

文献信息

• [EN] CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS<br/>[FR] COMPOSES D'ACIDE DICARBOXYLIQUE DE CYCLOALCENE SERVANT D'AGENTS ANTI-INFLAMMATOIRES, D'IMMUNOMODULATION ET ANTI-PROLIFERATION
  申请人：4SC AG

  公开号：WO2004056746A1

  公开（公告）日：2004-07-08

  The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein A is a non-aromatic ring system containing 4 to 8 carbon atoms, wherein the ring system comprises at least one double bond and wherein one or more of the carbon atoms in the ring can be replaced by a group X, wherein X is selected from the group consisting of S, O, N, NR4, SO, CO or SO2; D is O, S, SO2, NR4 or CH2; Z1 and Z2 are independent from each other O, S, or NR5 ; R2 is H, OR6, or NHR7; E is an alkyl or cycloalkyl group or a monocyclic or polycyclic substituted or unsubstituted ring system which may contain one or more groups X and which contains at least one aromatic ring; Y is hydrogen, halogen, haloalkyl, haloalkyloxy, alkyl, cycloalkyl, a monocyclic or polycyclic substituted or unsubstituted ring system for the use as a medicament.

  本发明涉及通式（I）的化合物及其盐和生理功能衍生物，其中A是含有4至8个碳原子的非芳香环系统，其中环系统至少包含一个双键，环中的一个或多个碳原子可以被X基团取代，其中X选自S、O、N、NR4、SO、CO或SO2组成的群；D为O、S、SO2、NR4或CH2；Z1和Z2彼此独立地为O、S或NR5；R2为H、OR6或NHR7；E为烷基或环烷基基团或可能含有一个或多个X基团的单环或多环取代或未取代环系统，其中至少含有一个芳香环；Y为氢、卤素、卤代烷基、卤代烷氧基、烷基、环烷基，用作药物的单环或多环取代或未取代环系统。
• Unsaturated azabicycloamine compounds and processes for the preparation thereof
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP0537556A1

  公开（公告）日：1993-04-21

  The present invention relates to an azabicycloamine compound of the formula (I) and the salts thereof: wherein:    R is a hydrogen or an amine protecting group;    R₁ and R₂, which may be the same or different, are hydrogen, optionally substituted lower alkyl, alkanoyl, optionally substituted benzoyl or naphthoyl, optionally substituted alkoxycarbonyl, or optionally substituted benzyloxycarbonyl; and    n is an integer from 1 to 4.

  本发明涉及一种式(I)的氮杂双环胺化合物及其盐：其中：R是氢或胺保护基；R₁和R₂，可以相同也可以不同，是氢、可选择取代的较低烷基、烷酰基、可选择取代的苯甲酰基或萘甲酰基、可选择取代的烷氧羰基，或可选择取代的苄氧羰基；n是从1到4的整数。
• Novel quinolone carboxylic acid derivatives and processes for preparing same
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP0550019A3

  公开（公告）日：1993-09-01

  The present invention relates to certain novel quinolone compounds of the present invention represented by the following formula(l) and novel processes for preparing same. wherein: X is a nitrogen atom or a C-Y group wherein Y is a hydrogen, fluorine, chlorine or bromine atom or a methoxy or methyl group;R1 is a C1 -6 alkyl group optionally substituted with a halogen atom or a hydroxy radical, an alkenyl group, a C3-6 cycloalkyl group, a phenyl group substituted with a halogen atom or a divalent group of -OCH2*CH(CH3)-, -SCH2*CH2-or -SCH2*CH(CH3)- which forms an oxazine or thiazine ring together with the nitrogen atom to which R1 is attached and with X wherein X is C-Y;R2 is a hydrogen atom, a carboxy protecting group or a pharmaceutically acceptable metal or organic cation;R3 and R4, which may be the same or different, are a hydrogen atom, a lower alkyl group, an acyl group or a nitrogen protecting group metabolizable in vivo;Z is a hydrogen or halogen atom, an amino, hydroxy or methyl group; andn is 1 to 3.

  本发明涉及一些新型喹诺酮化合物，其由以下式(l)表示，并且涉及制备这些化合物的新型方法。其中：X是氮原子或C-Y基团，其中Y是氢、氟、氯或溴原子或甲氧基或甲基基团；R1是C1-6烷基基团，可选择地取代为卤原子或羟基基团、烯基基团、C3-6环烷基基团、带有卤原子的苯基基团或与R1连接的氮原子一起形成氧杂环或硫杂环的二价基团，其中X是C-Y；R2是氢原子、羧基保护基团或药用可接受的金属或有机阳离子；R3和R4，可以相同也可以不同，是氢原子、较低烷基基团、酰基团或在体内可代谢的氮保护基团；Z是氢或卤原子、氨基、羟基或甲基基团；n为1至3。
• Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
  申请人：4 SC AG

  公开号：US20040176458A1

  公开（公告）日：2004-09-09

  The present invention relates to compounds of the general formula (I) and salt and physiologically functional derivatives thereof, 1 wherein A is a non-aromatic ring system containing 4 to; 8 carbon atoms, wherein the ring system comprises at least one double bond and wherein one or more of the carbon atoms in the ring can be replaced by a group X, wherein X is selected from the group consisting of S, O, N, NR 4 , SO, CO or SO 2 ; D is O, S, SO 2 , NR 4 or CH 2 ; Z 1 and Z 2 are independent from each other O, S, or NR 5 ; R 2 is H, OR 6 , or NHR 7 ; E is an alkyl or cycloalkyl group or a monocyclic or polycyclic substituted or unsubstituted ring system which may contain one or more groups X and which contains at least one aromatic ring; Y is hydrogen, halogen, haloalkyl, haloalkyloxy, alkyl, cycloalkyl, a monocyclic or polycyclic substituted or unsubstituted ring system for the use as a medicament.

  本发明涉及通式(I)的化合物以及其盐和生理功能衍生物，其中A是含有4至8个碳原子的非芳香环系统，环系统至少包含一个双键，环中的一个或多个碳原子可被X基团取代，X选自S、O、N、NR4、SO、CO或SO2；D是O、S、SO2、NR4或CH2；Z1和Z2彼此独立，为O、S或NR5；R2为H、OR6或NHR7；E是烷基或环烷基或含有至少一个芳香环的单环或多环取代或未取代环系统，该环系统可能含有一个或多个X基团；Y为氢、卤素、卤代烷基、卤代烷氧基、烷基、环烷基，单环或多环取代或未取代环系统，用作药物。
• Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
  申请人：4 SC AG

  公开号：US07071355B2

  公开（公告）日：2006-07-04

  The present invention relates to compounds of the general formula (I) and salt and physiologically functional derivatives thereof, wherein A is a non-aromatic ring system containing 4 to 8 carbon atoms, wherein the ring system comprises at least one double bond and wherein one or more of the carbon atoms in the ring can be replaced by a group X, wherein X is selected from the group consisting of S, O, N, NR4, SO, CO or SO2; D is O, S, SO2, NR4 or CH2; Z1 and Z2 are independent from each other O, S, or NR5; R2 is H, OR6, or NHR7; E is an alkyl or cycloalkyl group or a monocyclic or polycyclic substituted or unsubstituted ring system which may contain one or more groups X and which contains at least one aromatic ring; Y is hydrogen, halogen, haloalkyl, haloalkyloxy, alkyl, cycloalkyl, a monocyclic or polycyclic substituted or unsubstituted ring system for the use as a medicament.

  本发明涉及一般式（I）的化合物及其盐和生理功能衍生物，其中A是含有4至8个碳原子的非芳香环系统，该环系统包含至少一个双键，环中的一个或多个碳原子可以被X基替换，其中X选自S、O、N、NR4、SO、CO或SO2的组；D是O、S、SO2、NR4或CH2；Z1和Z2彼此独立，为O、S或NR5；R2为H、OR6或NHR7；E是烷基或环烷基或单环或多环取代或未取代的环系统，可能含有一个或多个X基，并且至少包含一个芳香环；Y为氢、卤素、卤代烷基、卤代烷氧基、烷基、环烷基、单环或多环取代或未取代的环系统，用作药物。